PT  - JOURNAL ARTICLE
AU  - Safin Arafat Rahman
AU  - Jacqueline Mcdermott2
AU  - Amanda Adler
AU  - Helen Barker
AU  - Christopher Johnson
AU  - Dorothy Grogono
AU  - Uta Hill
AU  - Charles Haworth
TI  - Impact of flash glucose monitoring system in cystic Fibrosis related diabetes
AID  - 10.1183/13993003.congress-2020.2774
DP  - 2020 Sep 07
TA  - European Respiratory Journal
PG  - 2774
VI  - 56
IP  - suppl 64
4099  - http://erj.ersjournals.com/content/56/suppl_64/2774.short
4100  - http://erj.ersjournals.com/content/56/suppl_64/2774.full
SO  - Eur Respir J2020 Sep 07; 56
AB  - Objective: In the UK, flash glucose monitoring system (Freestyle Libre sensor) has been made available to patients with cystic fibrosis related diabetes (CFRD). The aims of our study were firstly to evaluate whether there is an improvement in blood glucose control in patients with FreeStyle Libre sensor monitoring, and secondly whether this has an impact on the frequency of infective respiratory exacerbations in patients with CFRD.Method: Since April 2019, 62 patients with CFRD in our centre were registered to use Libre sensors. Of these, 30 patients have HbA1c measurements within 12 months prior to and 6 months after starting with the flash blood glucose monitoring. In addition, these 30 patients regularly upload their data to a central data storage programme Libre view. HbA1c values prior to and at least 3-6 months after starting to use the FreeStyle libre sensor were compared and statistical analysis was undertaken (paired t-test).We further assessed the impact of flash glucose monitoring system on lung health by comparing the number of infective exacerbations requiring intravenous antibiotics in the 6 months prior and 6 months after starting to use the FreeStyle Libre sensor in patients with CFRD.Results: We observed a significant improvement in HbA1c levels following the use of Freestyle Libre sensor monitoring. The difference of mean for HbA1c is 6.5 mmol/mol in patients with CFRD (p=0.006) with 95% CI. However, there was no difference in the frequency of infective exacerbations as the difference of mean was not significant with P value of 0.24.Conclusion: Flash glucose monitoring significantly improves blood glucose control in CFRD.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2774.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).